Clinical trial • Phase III • Rare Disease|Nephrology
GSK4771261 for Autosomal Dominant Polycystic Kidney Disease
Phase III trial of GSK4771261 for Autosomal Dominant Polycystic Kidney Disease. 30 participants.
Overview
- Trial Therapeutic Area
- Rare Disease|Nephrology
- Trial Disease
- Autosomal Dominant Polycystic Kidney Disease
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 13-03-2026
- First CTIS Authorization Date
- 06-05-2026
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 30
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 1
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Netherlands
- Earliest CTIS Part Ii Submission Date
- 05-05-2026
- Latest Decision Or Authorization Date
- 06-05-2026
- Processing Time Days
- 1
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Salah Hadi
- Contact Person Email
- Salah.Hadi@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Glaxosmithkline Research & Development Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- GSK4771261
- Routes Of Administration
- Subcutaneous
- Route
- Subcutaneous
Related trials
Other published trials that may interest you.